drug · antibody drug conjugate
enfortumab vedotin
Marketedupdated 5mo agoby Astellas Pharma Inc🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.
targets
Nectin-4Tubulin
all catalysts(12)
approval · 12
Dec 18, 2019
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Mar 22, 2021
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Jul 9, 2021
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Jul 9, 2021
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Oct 28, 2022
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Apr 3, 2023
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Apr 3, 2023
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Apr 18, 2023
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Dec 15, 2023
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Dec 15, 2023
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Feb 27, 2025
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Nov 21, 2025
approval
PADCEV (ENFORTUMAB VEDOTIN-EJFV) — FDA approval
enfortumab vedotin
→
Trials studying enfortumab vedotin
- phase2A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy
- phase2Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- phase2A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
- phase2PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients
- phase2Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
- phase3A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
- phase3Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
- phase1FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
News(10)
- Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.fiercebiotech · 1mo ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 1mo ago
- Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructureThe additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…biospace · 2mo ago
- ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFor years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…fiercebiotech · 2mo ago
- Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.biopharma_dive · 2mo ago
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…endpoints · 2mo ago
- Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workersHundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…biopharma_dive · 4mo ago
- Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBCPerioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.onclive · 4mo ago
- AstraZeneca follows Merck with Phase 3 win in bladder cancerA combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek appr…endpoints · 4mo ago
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that